P/E ratio for Bristol-Myers Squibb (BMY)
P/E ratio as of May 2024 (TTM): 11.1
According to Bristol-Myers Squibb's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 11.068. At the end of 2022 the company had a P/E ratio of 24.1.
P/E ratio history for Bristol-Myers Squibb from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 24.1 | 22.82% |
| 2021 | 19.7 | -226.77% |
| 2020 | -15.5 | -153.28% |
| 2019 | 29.1 | 69.66% |
| 2018 | 17.2 | -82.64% |
| 2017 | 98.8 | 351.57% |
| 2016 | 21.9 | -69.14% |
| 2015 | 70.9 | 45.37% |
| 2014 | 48.8 | 43.19% |
| 2013 | 34.1 | 21.27% |
| 2012 | 28.1 | 74.6% |
| 2011 | 16.1 | 9.38% |
| 2010 | 14.7 | 211.7% |
| 2009 | 4.72 | -46.82% |
| 2008 | 8.87 | -63.53% |
| 2007 | 24.3 | -26.05% |
| 2006 | 32.9 | 117.62% |
| 2005 | 15.1 | -27.42% |
| 2004 | 20.8 | 17.26% |
| 2003 | 17.8 | -17.89% |
| 2002 | 21.6 | -55.46% |
| 2001 | 48.6 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.3 | -7.25% | 🇺🇸 USA |
 Novartis NVS | 26.0 | 134.65% | 🇨🇭 Switzerland |
 Pfizer PFE | 13.8 | 24.45% | 🇺🇸 USA |
 AbbVie ABBV | 44.2 | 299.24% | 🇺🇸 USA |
 Eli Lilly LLY | 144 | 1,199.86% | 🇺🇸 USA |
 Amgen AMGN | 19.4 | 74.92% | 🇺🇸 USA |
 Sanofi SNY | 15.5 | 39.86% | 🇫🇷 France |
 Biogen BIIB | 11.6 | 5.14% | 🇺🇸 USA |
 Merck MRK | 70.9 | 540.90% | 🇺🇸 USA |
 AstraZeneca AZN | 38.2 | 245.38% | 🇬🇧 UK |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.